HIGH-LEVELS OF EPSTEIN-BARR-VIRUS IN THE OROPHARYNX - A PREDICTOR OF DISEASE PROGRESSION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION

被引:38
|
作者
DIAZMITOMA, F
RUIZ, A
FLOWERDEW, G
HOUSTON, S
ROMANOWSKI, B
KOVITHAVONGS, T
PREIKSAITIS, J
TYRRELL, DL
机构
[1] UNIV ALBERTA,DEPT MED MICROBIOL & INFECT DIS,EDMONTON T6G 2E1,ALBERTA,CANADA
[2] UNIV ALBERTA,DEPT HLTH SERV ADM & COMMUNITY MED,EDMONTON T6G 2E1,ALBERTA,CANADA
关键词
AIDS; cofactor; dot hybridization; homosexual;
D O I
10.1002/jmv.1890310202
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The role of Epstein‐Barr virus (EBV) on the progression of human immunodeficiency virus (HIV) infection is not well defined. The objective of this prospective study was to determine the prevalence of EBV excretion and the rol that EBV might have on HIV disease progression. Fifty‐two homosexual males were studied, all of whom had positive EBV serology. Twenty‐four of the 27 HIV‐seropositive and 14 of the 25 HIV‐seronegative subjects had detectable levels of EBV DNA in oropharyngeal cells. In addition to a greater prevalence of detectable EBV, the level of excretion was higher among HIV‐seropositives than among HIV‐seronegatives, and higher among group III than among group II HIV‐seropositive men. These results are consistent with earlier studies showing a relationship between immunosuppression and EBV reactivation. The EBV excretion levels in a control group of 52 age‐matched heterosexual males were substantially lower than those found in the homosexual group. In a proportional hazards regression analysis EBV excretion was found to be the best single predictor of progression of HIV infection (P<0.001). HIV p24 core antigenemia (P=0.048) and low EBNA (P=0.024) were significant predictors independent of EBV excretion. Whether EV directly accelerates the time to progression or is merely a marker of underlying subclinical immunosuppression remains an open question. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:69 / 75
页数:7
相关论文
共 50 条
  • [31] ACTIVATION OF ENDOGENOUS EPSTEIN-BARR-VIRUS BY HUMAN IMMUNODEFICIENCY VIRUS TYPE-1
    BERGER, R
    GILLITZER, R
    RAPPERSBERGER, K
    WOLFF, K
    STINGL, G
    CLINICAL RESEARCH, 1989, 37 (02): : A742 - A742
  • [32] RECURRENCE OF KAWASAKI-DISEASE AND EPSTEIN-BARR-VIRUS INFECTION
    KIKUTA, H
    MATSUMOTO, S
    YANASE, Y
    KAWASAKI, T
    MIZUNO, F
    OSATO, T
    JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (05): : 1215 - 1215
  • [33] ACQUIRED VONWILLEBRAND DISEASE AFTER EPSTEIN-BARR-VIRUS INFECTION
    KINOSHITA, S
    YOSHIOKA, K
    KASAHARA, M
    TAKAMIYA, O
    JOURNAL OF PEDIATRICS, 1991, 119 (04): : 595 - 598
  • [34] INFECTION OF HUMAN ENDOTHELIAL-CELLS WITH EPSTEIN-BARR-VIRUS
    JONES, K
    RIVERA, C
    SGADARI, C
    FRANKLIN, J
    MAX, EE
    BHATIA, K
    TOSATO, G
    JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (05): : 1213 - 1221
  • [35] EPSTEIN-BARR-VIRUS INFECTION RAPIDLY PROGRESSING TO MONOCLONAL LYMPHOPROLIFERATIVE DISEASE IN A CHILD WITH SELECTIVE IMMUNODEFICIENCY
    SCHUSTER, V
    KRETH, HW
    MULLERHERMELINK, HK
    HUPPERTZ, HI
    FELLER, AC
    NEUMANNHAEFELIN, D
    WIEGAND, H
    MULLERLANTZSCH, N
    EUROPEAN JOURNAL OF PEDIATRICS, 1990, 150 (01) : 48 - 53
  • [36] CLINICAL ASPECTS ON EPSTEIN-BARR-VIRUS INFECTION
    ANDERSSON, JP
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, : 94 - 104
  • [37] EPSTEIN-BARR-VIRUS INFECTION - A LYMPHOTROPIC AND EPITHELIOTROPIC INFECTION
    NAHER, H
    PETZOLDT, D
    HAUTARZT, 1992, 43 (03): : 114 - 119
  • [38] APNEA ASSOCIATED WITH EPSTEIN-BARR-VIRUS INFECTION
    SIMON, MW
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (01) : 82 - 82
  • [39] HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED HODGKINS-DISEASE CONTAINS LATENT, NOT REPLICATIVE, EPSTEIN-BARR-VIRUS
    SIEBERT, JD
    AMBINDER, RF
    NAPOLI, VM
    QUINTANILLAMARTINEZ, L
    BANKS, PM
    GULLEY, ML
    HUMAN PATHOLOGY, 1995, 26 (11) : 1191 - 1195
  • [40] OPHTHALMIC MANIFESTATIONS OF EPSTEIN-BARR-VIRUS INFECTION
    PFLUGFELDER, SC
    CROUSE, CA
    ATHERTON, SS
    INTERNATIONAL OPHTHALMOLOGY CLINICS, 1993, 33 (01) : 95 - 101